Lexicon Pharmaceuticals, Inc. (LXRX) Market Cap & Valuation Ratios
Lexicon Pharmaceuticals, Inc. (LXRX) has a market cap of $631.8M and a price-to-sales ratio of 15.2, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LXRXLexicon Pharmaceuticals, Inc.Follow LXRX — free
—
Price chart with a free account
- Market cap
- 631.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| LXRX | 0.6 | — | 11.9 | — | -10.3% | -29% | -131% | -30% |
| DNA | 0.7 | — | 5.3 | — | — | -52% | -260% | -78% |
| ACHV | 0.7 | — | — | — | -7.4% | — | — | — |
| PRME | 0.7 | — | 140.1 | — | — | -18% | — | — |
| AURA | 0.7 | — | — | — | — | — | — | -88% |
| DSGN | 0.6 | — | — | — | -8.6% | — | — | -42% |
| SLDB | 0.6 | — | — | — | — | — | — | -127% |
| WVE | 0.6 | — | 4.0 | — | — | -30% | -333% | -255% |
| CADL | 0.6 | — | — | — | -9.3% | — | — | — |
| CRMD | 0.6 | 3.8 | 1.1 | 2.0 | — | +281% | 47% | 57% |
| SGMT | 0.6 | — | — | — | -7.0% | — | — | -59% |
| Median of these 10 | 3.8 | 4.6 | 2.0 | -8.0% | -24% | -260% | -78% |
; EV/Sales 11.9 vs. 4.6.
Growth vs. price
each dot a company · hover or tap for valuesLexicon Pharmaceuticals, Inc. — questions
- What is Lexicon Pharmaceuticals, Inc.'s market cap?
- $631.8M.
- What is Lexicon Pharmaceuticals, Inc.'s price-to-sales ratio?
- 15.2.
Every figure on this page comes from Lexicon Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.